Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989727 | 0.79 | KCNJ1 (0.54) | KMT2AALDH1A1KCNJ1ACLYNOTUM | |
| SCHEMBL6990234 | 0.78 | ALDH1A1 (0.60) | KMT2AALDH1A1KCNJ1NOTUMTP53 | |
| SCHEMBL28476725 | 0.77 | RAB9A (0.46) | KMT2AALDH1A1KCNJ1TSHRACLY | |
| SCHEMBL357612 | 0.76 | P2RY14 (0.50) | KMT2AALDH1A1KCNJ1TSHRNOTUM | |
| SCHEMBL6425207 | 0.75 | KMT2A (0.52) | KMT2AALDH1A1KCNJ1TSHRTP53 | |
| SCHEMBL4317005 | 0.74 | ALDH1A1 (0.44) | KMT2AALDH1A1TSHRACLYNOTUM | |
| SCHEMBL6498971 | 0.74 | HDAC7 (0.57) | KMT2AALDH1A1NOTUMSMN1; SMN2 | |
| SCHEMBL2757861 | 0.74 | MAPT (0.53) | KMT2AALDH1A1KCNJ1NOTUMTP53 | |
| SCHEMBL82595 | 0.73 | MAPT (0.69) | KMT2AALDH1A1KCNJ1NOTUMLMNA | |
| SCHEMBL9423281 | 0.73 | ALDH1A1 (0.55) | KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | P2RX3, P2RX2, P2RX5 | KMT2A 2876/4885ALDH1A1 2080/4885KCNJ1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.